PAR-24-262: STTR Solutions to Enable Population Genomic Screening (R41/R42 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to small businesses. Applications closed on December 2, 2024.
From the official notice on Grants.gov, last changed August 16, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- R41, Small Business Technology Transfer (STTR) Phase I. A small business and a research institution test the feasibility of a technology together. Other open R41 notices.
- R42, Small Business Technology Transfer (STTR) Phase II. Full development of an STTR project after Phase I. Other open R42 notices.
Application due dates, page limits and budget limits are set in the notice. Read PAR-24-262 in the NIH Guide.
Key dates
| Posted | August 16, 2024 |
|---|---|
| Deadline | December 2, 2024 |
| Archived by Grants.gov | January 7, 2025 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity (NOFO) is to solicit Small Business Technology Transfer (STTR) grant applications from small businesses to develop innovative solutions for commercialization that would enable population screening for common, actionable genomic conditions in a primary care setting.
Who has won Human Genome Research grants before
From fiscal 2021 to 2025, Human Genome Research (93.172) awarded $2.2 billion across 1,255 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 59 | $153 million |
| University of Washington | Washington | 46 | $123 million |
| The Broad Institute, Inc | Massachusetts | 22 | $119 million |
| University of California Santa Cruz | California | 17 | $64.7 million |
| Baylor College of Medicine | Texas | 24 | $62.9 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-24-262 still open?
No. It closed on December 2, 2024.
Who can apply for STTR Solutions to Enable Population Genomic Screening (R41/R42 Clinical Trial Optional)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for STTR Solutions to Enable Population Genomic Screening (R41/R42 Clinical Trial Optional)?
Closed December 2, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Human Genome Research grants before?
The largest recipients over five fiscal years were The Leland Stanford Junior University, University of Washington, The Broad Institute, Inc. The program made 1,255 awards worth $2.2 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)